Enrichment of cell subpopulations is a prerequisite for lineage-specific chimerism analysis (LCA), a frequent approach in follow-up after allo-SCT. An efficient enrichment technique is Magnetic Cell Sorting (MACS) using the AutoMACS separator. However, evaluation of purity, recovery and applicability for PCR-based chimerism analysis of MACS-enriched subpopulations from post-transplant peripheral blood, providing reduced cell numbers and/or unbalanced proportions of subpopulations, is currently unavailable. We performed enrichment of CD3-, CD14-, CD15-, CD19-and CD56-positive subpopulations using 'Whole Blood MicroBeads' and AutoMACS separator in 137 prospectively collected peripheral blood samples from 15 paediatric patients after allo-CD3-/CD19-depleted SCT. Purity was assessed by immune phenotyping. Recovery and applicability for chimerism analysis was evaluated. Excellent purity 490% was achieved in CD14-, CD15-positive cells in 81%, 95% of the isolates and in 86% of CD3 and CD19 isolates, if ACC was 4400 cells per ll. Median purity of CD56-positive isolates was 78.9%. Recovery 490% was between 93 (CD56) and 37% (CD15). Conventional and real-time PCR-based chimerism analysis was feasible in virtually all samples. Isolation of cell subpopulations by automated cell enrichment in post-transplant peripheral blood is feasible and fast providing excellent purity and recovery for routine lineage-specific chimerism analysis.
Introduction
Chimerism analysis has acquired particular importance for the post-transplant surveillance of engraftment. It offers the possibility of recognizing impending graft rejection and can serve as an indicator for the recurrence of the underlying malignant or non-malignant disease. [1] [2] [3] [4] [5] [6] [7] A state of mixed haematopoietic chimerism may reduce the clinical GVL effect of alloreactive donor-derived effector cells, and thus facilitate the proliferation of residual (malignant) cells that may have survived the conditioning regimen. Therefore, chimerism analysis can provide information about tolerance induction and alloreactive processes after transplant. Moreover chimerism analysis in subpopulations could provide indications for early graft rejection, GVHD and relapse. 4, [8] [9] [10] [11] [12] [13] [14] [15] Therefore, enrichment of cell subpopulations is essential to enable lineage-specific chimerism analyses. Most prevalent are two different enrichment technologies: Fluorescence-Activated Cell Sorting (FACS) and Magnetic Cell Sorting (MACS, Miltenyi Biotec, Bergisch Gladbach, Germany). FACS offers the highest enrichment purity of the isolated subpopulation, but this method is labour intensive and time consuming. MACS can be carried out applying the MiniMACS/QuadroMACS technique or the MACS technique (Miltenyi Biotec). Cell sorting by the latter approach is much easier to carry out, cheaper and faster compared with flow cytometry. On the other hand, MACS provides no information about the purity and recovery of enriched cell subpopulations from post-transplant peripheral blood (PB) samples, which usually contain reduced cell numbers and/or unbalanced proportions of particular subpopulations. Purity depends on the cell frequency of the targeted subpopulation in PB derived from regenerating BM as well as on the quality of the monoclonal anti-human antibodies used.
This study was conducted to evaluate the quality of MACS-based enrichment of subpopulations and its applicability for chimerism analysis using STR and sequence polymorphism (SP) markers. In particular, the following questions should be answered: What is the purity and recovery of MACS-based ('Whole Blood MicroBeads') enrichment of cell subpopulations from post-transplant PB samples? Are these parameters dependent on the following variables: (1) monoclonal anti-human antibodies, (2) concentration of cell subsets in the initial PB sample? Which is the minimal DNA amount allowing PCR-based chimerism analysis?
Materials and methods

Patients
Between April 2005 and June 2006, 15 children and adolescents underwent allo-CD3-/CD19-depleted SCT for different paediatric haematological malignancies and one non-malignant disease at the University Hospital for Children and Adolescents, Frankfurt, Germany. Thirteen patients received non-myeloablative reduced intensity conditioning and two patients received myeloablative conditioning as preparative regimen before SCT (Table 1) . The study protocol was approved by the clinical ethics committee of the University of Frankfurt and the trial was conducted according to the principles of the Declaration of Helsinki. Informed consent was obtained from patients and parents according to institutional guidelines.
Frequency and number of samples Peripheral blood samples were collected prospectively. Cell separation using the AutoMACS separator, FACS analysis as well as lineage-specific and whole blood chimerism analyses were carried out weekly during the first 100 days and, thereafter, once a month. Finally, a total of 137 PB samples have been processed. However, the analysis of purity, recovery and chimerism status was not possible in all samples because of the limited availability of patients material (Tables 1, 2 and Figure 1 ).
Magnetic Cell Sorting enrichment of peripheral blood cell subpopulations Lineage-specific cell isolation was carried out from EDTA PB. Cell separation of subpopulations CD3, CD14, CD15, CD19 and CD56 was conducted using specific 'Whole Blood MicroBeads' conjugated to monoclonal anti-human antibodies (Miltenyi Biotec). The blood volume used for purification was about 500 ml up to 1 ml for each subpopulation depending on the total available blood volume. Regularly, each target subpopulation was magnetically labelled by adding 50 ml of corresponding 'Whole Blood MicroBeads' suspension to 1 ml of whole blood. In case of lower available blood volumes, all reagent volumes were equivalently adapted. After 15 min of incubation time at 4-81C, cells were washed by adding 5 ml of AutoMACS Running Buffer (Miltenyi Biotec) per millilitre of whole blood. Afterwards, centrifugation with slow deceleration (450 g) at room temperature for 10 min was carried out, followed by discharge of supernatant. Resuspension was carried out by adding one volume of buffer. Magnetic cell separation was carried out using the AutoMACS separator (Miltenyi Biotec) referring to the AutoMACS User Manual applying the separation program 'posseld2'. The positive fractions (final volume of 2 ml) were divided equally using one sample for DNA isolation and the other for flow cytometry.
Manual cell count
Cell amounts were determined using a Neubauer improved counting chamber (Optik Labor, Friedrichshafen, Germany).
Fluorescence-Activated Cell Sorting analysis of purity after magnetic cell separation Purity of the respective subpopulation was assessed using a direct immunofluorescence technique with specific monoclonal antibodies conjugated with R-Phycoerythrin (RPE) or Fluorescein isothiocyanate (FITC, Becton Dickinson, San Jose, CA, USA). The fraction of dead cells was detected by propidium iodide. Analyses were carried out in an FACScalibur flowcytometer (Becton Dickinson). Lineage-specific isolated cells were labelled each with antiCD45 RPE monoclonal antibodies and antiCD3, antiCD14, antiCD15, antiCD19 and antiCD56 FITC-conjugated monoclonal antibodies, according to the purified subpopulation.
DNA solubilization
Supernatant from the isolated cell fraction was removed, and 20 ml of Viagen cell lysis solution (PeqLab, Erlangen, Germany) as well as 1 ml of Proteinase K (20 mg/ml) was added. After mixing, the sample was incubated at 561C for 60 min. Inactivation of Proteinase K was carried out at 951C for 15 min. For incubation, a conventional PCR Cycler with heated cover (Gene Amp PCR System 9700, Applied Biosystems, Foster City, CA, USA) was used. The resulting cell lysate was used for PCR without further modifications.
Determination of DNA amount DNA concentration of the pre-SCT recipient and donor samples, as well as all post-SCT whole blood and subpopulation samples, was determined by a control gene assay detecting chromosomal DNA by Albumin quantitative real -time PCR (qPCR). 16 Quantitation was performed by a standard DNA dilution series including 200, 50 and 10 ng DNA dilution steps.
Chimerism assays STR-based chimerism analysis by competitive PCR.
A semi-quantitative PCR assay, based on the amplification of STR markers, was used for quantitation of chimerism as described earlier. 1, 17 Detection of genetic markers was performed using the PowerPlex 16 System (Promega Corporation, Madison, WI, USA). Amplified fragments were separated by capillary electrophoresis conducted on the ABI PRISM 3100 Genetic Analyzer (Applied Biosystems). For detailed evaluation, the corresponding peak area values were transferred to the Applied Biosystems GeneMapper Software. An STR-PCR-based chimerism analysis was regarded as accurate and reliable according to the proposal of the Eurochimerism consortium. 17 Informative STR markers were selected according to the nomenclature (RSD code) published earlier by Watzinger et al. 18 Results of STR-PCR-based chimerism analyses were accepted only if the size of allele specific peaks presented as proposed by Scharf et al. 19 The percentage of donor and recipient DNA was calculated from individual proportions of donor and recipient peak areas in relation to the summation of all signals. This competitive STR-PCR-based system provided a quantifiable limit of 1E-02.
Sequence polymorphisms-based chimerism analysis by real-time PCR A more sensitive qPCR system, based on SPs as genetic markers, was simultaneously used to characterize haematopoietic chimerism, as described earlier. 20 Analyses were conducted on the ABI PRISM 7700 Sequence Detector (Applied Biosystems) and iCycler iQ5 Multicolor Real-time PCR Detection System (Bio-Rad, Hercules, CA, USA) applying TaqMan chemistry. FAM (6-carboxyfluorescein) served as reporter dye and TAMRA (6-carboxy-tetramethyl-rhodamine) (Sigma-Genosys, Steinheim, Germany) Table 2 Cell specimens-recovery, purity and feasibility of chimerism analysis a Ratio of absolute cell count (ACC) after magnetic isolation and ACC in PB.
b
In samples with a DNA concentration X0.5 ng/ml.
c If ACC was 4400/ml.
Automated enrichment of cell subsets for chimerism analysis A Willasch et al as quencher dye. Data were analysed using the ABI PRISM 7700 Sequence Detector Software and Bio-Rad iQ5 Optical System Software. Normalization was done to the measured DNA quantity of each sample to rule out incorrect quantitation caused by varying DNA input. DNA input was measured by a control gene assay as described above. This qPCR-based system previously allowed the performance of chimerism analyses in virtually all patients and provided a quantifiable limit of p1E-03 in 83.3% of the assays. 20 SP-qPCR-based chimerism analysis was regarded as reliable if the difference in cycle threshold (CT) values in duplicate analyses was p1. Furthermore, it was regarded as reliable if CT was 50 (corresponding to an autologous signal of 0%) in one duplicate and the normalized autologous signal of the second duplicate did not exceed 0.5%, as such a constellation indicated the quantifiable limit of the method. In this case, no reproducible and therefore reliable autologous signal could be detected and the sample was classified as a complete chimera.
Evaluation of DNA amount for PCR-based chimerism analysis Competitive PCR. The PowerPlex 16 System (Promega Corporation) for STR-PCR-based chimerism analysis was optimized for at least 0.5 ng DNA in a volume of 16 ml corresponding to 0.0313 ng/ml. 
Real-time PCR
Our goal was to use at least 25 ng of DNA for qPCR chimerism analysis. This was not possible in all samples, particularly in cell subpopulations of regenerating haematopoiesis after SCT. Here, the DNA amount obtained after DNA solubilization was sometimes low, either because of the low frequency of the respective cells in PB or because of the technical problems during the enrichment process. To get reliable results, a substantial amount of DNA has to be used for PCR-based chimerism analyses. Theoretically, one single copy of the respective target sequence is sufficient to obtain a qPCR curve. In terms of cell counts, this means that one cell, corresponding to 6.7 pg (0.0067 ng) of DNA, generally should result in a qPCR signal. In the context of haematopoietic chimerism analysis, the intention is to detect the potential existence of patient-derived (autologous) cells in a PB sample dominated by donor-derived cells. Consequently, the lowest possible threshold 21 of a method to detect autologous cells among others depends on the amount of cells (DNA) used for the experiment. For example, if one aims to quantify an autologous signal of 5% in a sample containing 100 cells corresponding to 670 pg DNA (0.67 ng DNA), the method must allow the detection of five cells. It is known that the distribution of cell counts of random samples, aimed at containing five cells, does not follow a normal distribution but a Poisson distribution. This means that, according to Poisson, the probability that a random sample intended to contain five cells, in fact includes only one or no cells is relatively high. Consequently, quantitation of autologous signals by qPCR in samples with o0.67 ng of DNA should show a great variability, which could hamper the generation of reproducible results. To confirm these theoretical considerations in a practical experiment, this threshold was, for reasons of practicability, fixed at 0.5 ng of DNA and the following approach was selected: 100, 25, 10, 5, 1 and 0.5 ng of DNA from the same post-transplant sample was used to perform SP-qPCR-based quantitation of chimerism. This procedure was carried out in 59 PB samples.
Statistical methods
Purity of the samples was investigated as a function of the absolute cell count (ACC, Figure 1 ). Relation between purity and ACC was visualized with trend curves obtained with the LOWESS algorithm implemented in the software package 'R', a language and environment for statistical computing and graphics (The R Foundation for Statistical Computing, Vienna, Austria 22 ). Finally, we derived the percentage of samples with purity above 90% for each subpopulation. For CD3 and CD19, the percentage was computed individually for samples with an ACC below and above 400 cells per ml.
Results
Purity and cell count of subpopulations isolated by automated cell enrichment After isolation of CD14-positive monocytes using the AutoMACS separator, 106 PB samples were analysed by FACS showing a median purity of 96.4%. The median ACC of these samples was 401 cells per ml. Purity 490% was achieved in 81.0% of the samples with no apparent relation to ACC ( Figure 1, Table 2 ). CD15-positive neutrophil granulocytes were isolated from 98 PB samples providing a median purity of 98.7%. Median ACC was found to be 2.781 cells per ml. In 95.0% of the samples, purity 490% was obtained. Isolation of CD3-positive T lymphocytes from 115 PB samples provided a median ACC of 393 cells per ml with a median purity of 90.1%. CD3-positive samples with an ACC o400 cells per ml (n ¼ 58) had a purity 490% in only 19.0% of the analysed samples, whereas samples with an ACC 4400 cells per ml (n ¼ 57) offered a purity 490% in 86.0% of the isolates. The trend line of purity (smoothed curve, Figure 1 , CD3) indicated a linear increase of 20% between two log steps of ACC in samples with an ACC o400 cells per ml. CD19-positive B lymphocytes were isolated from 110 PB samples providing a median purity of 40.9% and a median ACC of 7 cells per ml. Samples with ACC 4400 cells per ml (n ¼ 7) had purity 490% in 86.0% of the isolates, whereas samples with ACC o400 cells per ml (n ¼ 103) provided purity 490% in only 9.0% of the analysed samples. Isolation of CD56-positive natural killer (NK) cells from 91 PB samples provided a median ACC of 201 cells per ml with a median purity of 78.9%. Purity 490% was achieved independently from ACC in only 14.0% of the samples. The trend line of purity (smoothed curve, Figure 1 , CD56) showed a tendency towards increase of purity (positive slope) depending on the ACC, which was, however, not as strong as in the other cell populations. In contrast to CD3 and 19 isolates, a threshold of ACC, above which a purity 490% was definitely achieved, could not be identified.
As isolation of CD56-positive cells could not be carried out with sufficient purity even in samples with higher ACC, this subpopulation was omitted from the following cumulative analysis of automated enrichment of cell subpopulations. In summary, isolation of CD3-, CD14-, CD15-and CD19-positive cells from 429 samples provided a median ACC of 393 cells per ml with a median purity of 93.8%. Samples with ACC o400 cells per ml (n ¼ 213) had a purity 490% in 29.0% of the analysed samples, whereas samples with ACC 4400 cells per ml (n ¼ 216) offered a purity 490% in 90.0% of the isolates. The trend line (smoothed curve) of purity in samples with ACC o400 cells per ml indicated a linear increase in purity from B20% in samples with ACC of 1 cell/ml to 80% in samples with ACC of 100 cells per ml.
Taken together, excellent purity 490% by automated cell enrichment could be obtained in CD14-and CD15-positive cells in virtually all samples. In CD3-and CD19-positive cells, this purity was solely achieved if ACC was 4400 cells per ml. Isolation of CD56-positive cells provided a median purity of 78.9% and the probability of purity 490% did not increase with ACC.
Recovery of automated cell enrichment and DNA isolation Recovery of MACS-based cell enrichment was defined as the ratio of ACC after magnetic isolation and ACC in PB, shown in Table 2 . Recovery 490% was achieved in CD56, Automated enrichment of cell subsets for chimerism analysis A Willasch et al CD14 and CD19 subpopulations in downward order ranging from 93 to 80% of the isolates. Lower recoveries were achieved for CD3-and CD15-positive cells. Nevertheless, recovery 470% was achieved in 89 and 63% of these isolates, respectively. Subsequent DNA isolation from CD3, CD14, CD15 and CD56 subpopulations provided a DNA concentration of at least 0.5 ng/ml in the vast majority of the processed samples, which was an indispensable prerequisite for reliable qPCR-based chimerism analyses as described in the following chapter. Solely, DNA isolation from CD19-positive cells provided a DNA concentration of at least 0.5 ng/ml in about half of the processed samples ( Table 2) .
Influence of DNA amount on quantitation of chimerism Precision of measurement of autologous signals for different DNA amounts was investigated by studying the difference between duplicate measurements as a function of DNA amount. As illustrated in Figure 2 , DNA input of at least 5 ng guaranteed accurate quantitation of chimerism in most cases. Median and mean differences between duplicate measurements of the autologous signal were 0.9 and 2.1 percentage points, respectively, for samples with DNA input 45 ng and showed no dependence on the DNA amount used for qPCR.
Owing to low frequency of the cell subpopulations in post-transplant PB, a qPCR-DNA input of at least 5 ng was not achievable in all samples. Table 3 shows the clustered differences between replicate measurements of autologous signals according to DNA input. Independently from the amount of DNA, the majority of replicate measurements of autologous signals (85.6%) differed by o5 percentage points. For samples with low DNA amounts, the fraction of samples with differences between replicate measurements 45 percentage points increased significantly from 7.8% for DNA amounts X5 ng to 26.3% for samples with DNA input o0.5 ng. Consequently, in samples with low cell frequencies, a DNA input of at least 0.5 ng seemed to be sufficient to obtain acceptable results of quantitation of chimerism. However, it has to be kept in mind that the lowest possible threshold to quantify autologous signals is limited in samples containing little DNA. For example, the lowest possible threshold for samples containing 0.5 ng of DNA is an autologous signal of B5% (see 'Materials and methods' section).
Feasibility of chimerism analyses in cell subpopulations
Generally, feasibility of STR-PCR-and SP-qPCR-based chimerism analyses of MACS-isolated cell subpopulations was excellent. With regard to SP-qPCR, a minimal DNA amount of 0.5 ng was needed for quantitation of chimerism as described above. Isolates fulfilling this prerequisite provided a good feasibility of chimerism analyses. Feasibility was defined according to objective criteria as described in the methods section. 17, 18 STR-PCR-based chimerism analysis was feasible in the vast majority of the subpopulations ranging from 98.2 (CD3) to 90.3% (CD19) of the processed samples. SP-qPCR-based chimerism analysis was feasible in all CD3-and CD14-positive isolates, in which DNA with a concentration of at least 0.5 ng/ml could be solubilized. In CD19, CD15 and CD56 subpopulations, SP-qPCR-based chimerism analysis was feasible as well in the vast majority of isolates, ranging from 98.0 (CD15) to 95.2% (CD19) of processed samples (Table 2) .
Clinical impact of lineage-specific chimerism analyses
Post-transplant follow-up of lineage-specific chimerism in a patient (UPN3469), who received CD3-/CD19-depleted PB stem cells after RIC, showed significantly increasing autologous signals in CD3-positive cells on day 33 and in PB on day 40. Autologous signals in CD19-and CD56-positive cells could not be reproduced in the following samples. Rapid tapering of the immunosuppressive agent mycophenolate mofetil (MMF) was started on day 56; MMF was discontinued on day 106. Nevertheless, persistent autologous signals in the CD3 subpopulation (80%) and in PB (10%) could be detected in the subsequent 
Discussion
Chimerism analysis is an important tool for monitoring of engraftment, graft rejection and relapse after allo-SCT. 1, 2 Mixed haematopoietic chimerism could reduce the GVL effect and facilitate the proliferation of residual (malignant) cells that were not eradicated during the conditioning regimen. Chimerism analysis in cell subpopulations could indicate early graft rejection, GVHD and relapse. 4, 6, [8] [9] [10] [11] [12] [13] [14] [15] Thus, enrichment of cell subpopulations is a prerequisite for lineage-specific chimerism analyses. However, enrichment of subpopulations is labour-intensive by conventional methods and therefore integration into routine diagnostics implies considerable effort. To facilitate this approach, 'Whole Blood Microbeads' were developed directly for rapid positive selection of cells from whole PB or BM. No sample preparation is required, including density gradient centrifugation or erythrocyte lysis. This approach was optimized for samples from healthy donors. After SCT, however, the regeneration process is accompanied by reduced cell numbers and/or unbalanced proportions of particular subpopulations. In this study, we evaluated the quality of automated cell enrichment with regard to purity, recovery and its applicability for chimerism analysis in post-transplant samples.
Isolation of CD14-positive monocytes and CD15-positive neutrophil granulocytes by automated cell enrichment, subsequent DNA solubilization and PCR-based chimerism analyses offered excellent results: median purity of 96.4 and 98.7% was reached and purity 490% was achieved in 81.0 and 95.0% of the isolates, respectively. Recovery 490% was attained in 81.0% of the CD14-positive cells and recovery 70% was achieved in 63.0% of the CD15-positive cells. This lower recovery in CD15-positive isolates was explained by the ACC of this subset, which was the highest of all isolated cell subpopulations. Saturation of the MoAb's binding capacity caused by high ACC could explain the reduced recovery. DNA solubilization resulted in sufficient DNA concentration (X0.5 ng/ml) in the vast majority of isolations, which allowed the generation of reliable STR-PCR-and SP-qPCR-based chimerism analyses in virtually all CD14-and CD15-positive samples.
Isolation of CD3-positive T lymphocytes and CD19-positive B lymphocytes showed a median purity of 90.1 and 40.9%. Purity 490% was attained in 86.0% of the isolates, respectively, if the ACC was 4400 cells per ml. This indicated, particularly in CD19-positive cells, the importance of a substantial amount of cells (at least 400 cells per ml) to guarantee isolates with high purity. In patients who received CD3-/19-depleted stem cells, the expansion of T and especially B lymphocytes in PB in the early phase after SCT might be low, which might hamper lineage-specific chimerism analyses in these subpopulations at that time. Recovery 490% was attained in 62.0% of the CD3-and Magnetic Cell Sorting-based isolation of CD56-positive NK cells provided a median purity of 78.9%. Purity 490% was achieved solely in 14.0% of the samples and this fraction did not increase with ACC. In contrast to CD3 and CD19 isolates, it was not possible to detect a threshold of ACC, which had to be exceeded to achieve a purity 490%. One reason for this low purity of CD56 isolation might have been the weaker binding capacity of the antiCD56 MoAb compared with the other used antibodies. In addition, before purification, CD56-positive cells include both CD56-positive/CD3-negative NK cells and CD56-positive/CD3-positive T cells. Most importantly, among the NK cells, immunoregulatory CD56 high CD16-negative and cytotoxic CD56 dim CD16-positive subpopulations could be distinguished in earlier studies. The purity after MACS selection seemed to be dependent on the composition of these various subpopulations and especially on the disposition between CD56 high and CD56 dim before purification. 23, 24 As we could show earlier, a two-step purification (first step: CD3 depletion, second step: CD56 enrichment of the former negative fraction) led to an increased median purity of CD56-positive/CD3-negative NK cells, but a dissatisfied recovery. 25 By contrast, recovery of cell isolation and DNA solubilization in our new study was excellent and guaranteed reliable chimerism analyses for virtually all samples in this subpopulation.
In summary, superior purity 490% by automated cell enrichment could be achieved in CD14-and CD15-positive cells in almost all samples. In CD3-and CD19-positive cells, this excellent purity was merely obtained if ACC was 4400 cells per ml. This indicates that a contemporaneous differential blood count from samples, in which chimerism in CD3 and CD19 subsets is analysed, is mandatory.
Substantial DNA concentration after DNA isolation is an indispensable prerequisite, particularly for qPCR-based chimerism analyses. Our goal was to use 25 ng of DNA for qPCR, corresponding to 40 recipient-derived cells in a sample with an autologous signal of 1%. However, the regeneration process after SCT is characterized by reduced cell numbers as well as by an unbalanced proportion of particular subpopulations. Consequently, it was not possible to obtain 25 ng of DNA for qPCR from each post-transplant PB sample. According to our data, a DNA input of at least 0.5 ng into qPCR was the absolutely lowest proportion of DNA to perform quantitation of chimerism. A reduced quantifiable limit for the detection of autologous signals of B5% in samples containing only 0.5 ng of DNA has to be kept in mind.
Development of stable post-transplant donor chimerism depends on different variables, such as the conditioning regimen and composition of the graft (for example, T-cell depletion). A state of (increasing) mixed chimerism (MC) after transplant, indicating the expansion of residual autologous cells, weakens the GVL effect and is highly predictive for impending relapse.
1 Therefore, the establishment of stable engraftment is an indispensable prerequisite for an optimal GVL effect. On the other hand, there are several external factors known to influence the occurrence of MC, such as reduced intensity conditioning and T-cell depletion. Little is known about the internal factors supporting the occurrence of MC, for example, in which subpopulation MC starts to rise. It is also a matter of debate whether MC in T or NK cells is predictive for relapse or rejection. 8 Therefore, it seems to be important to investigate the dynamics of chimerism in different subpopulations. This may allow timely intervention to prevent graft rejection or relapse. Early and reliable identification of patients who develop increasing MC by a highly sensitive method is the prerequisite for timely intervention. This offers the possibility of starting DLI with low cell doses to minimize the risk of inducing post-DLI aplasia. [26] [27] [28] The potential of lineage-specific chimerism could be shown exemplarily in a patient, after CD3-/19-depleted PB SCT, who developed significantly increasing autologous signals in CD3-positive cells on day 33 and in PB on day 40 after transplant ( Figure 3) . Apparently, CD3-positive cells showed totally different kinetics of chimerism compared with the other subpopulations. Although CD19 and CD56 subpopulations showed solely minor autologous signals during follow-up without increasing tendency, CD14-and CD15-positive cells showed no autologous signals at all. Thus, the increase of recipient cells in PB was caused by a strong increase of autologous signals in the CD3 subset. Intervention consisted of a tapering and subsequent discontinuation of the immunosuppressive agent (MMF). However, persistent autologous signals in the CD3 subpopulation and in PB were found during follow-up and DLI was conducted twice. Re-establishment of complete donor PB and CD3 chimerism was diagnosed 50 days after the last DLI, holding on until day 820 (latest follow-up sample) without any signs of GVHD. This example underlined the potential of characterization of lineage-specific chimerism to guide pre-emptive immunotherapy. Furthermore, lineage-specific chimerism analysis could be helpful in diagnosing graft rejection, GVHD and relapse. 11, 15 In summary, the isolation of cell subpopulations by automated cell enrichment applying 'Whole Blood MicroBeads' is feasible, providing a good purity and recovery of the respective isolates and giving the opportunity to perform reliable lineage-specific monitoring of chimerism after SCT. This might be of particular importance in patients who received T-cell-depleted stem cells after reduced intensity conditioning. Monitoring of chimerism in cell subpopulations provides the background for optimal initiation of immunotherapy to prevent graft rejection or relapse.
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